Head to Head Contrast: Peregrine Pharmaceuticals (PPHM) & Its Competitors
Peregrine Pharmaceuticals (NASDAQ: PPHM) is one of 45 public companies in the “Biopharmaceuticals” industry, but how does it contrast to its peers? We will compare Peregrine Pharmaceuticals to similar businesses based on the strength of its risk, analyst recommendations, dividends, earnings, valuation, profitability and institutional ownership.
This table compares Peregrine Pharmaceuticals and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Peregrine Pharmaceuticals Competitors||-13,134.93%||230.04%||-23.03%|
Valuation & Earnings
This table compares Peregrine Pharmaceuticals and its peers gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|Peregrine Pharmaceuticals||$79.10 million||-$15.94 million||-4.81|
|Peregrine Pharmaceuticals Competitors||$578.59 million||$241.91 million||-6.31|
Peregrine Pharmaceuticals’ peers have higher revenue and earnings than Peregrine Pharmaceuticals. Peregrine Pharmaceuticals is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.
Insider and Institutional Ownership
45.2% of shares of all “Biopharmaceuticals” companies are held by institutional investors. 4.9% of Peregrine Pharmaceuticals shares are held by company insiders. Comparatively, 13.9% of shares of all “Biopharmaceuticals” companies are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
This is a breakdown of recent ratings and recommmendations for Peregrine Pharmaceuticals and its peers, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Peregrine Pharmaceuticals Competitors||190||908||1680||67||2.57|
As a group, “Biopharmaceuticals” companies have a potential upside of 0.16%. Given Peregrine Pharmaceuticals’ peers higher probable upside, analysts plainly believe Peregrine Pharmaceuticals has less favorable growth aspects than its peers.
Volatility and Risk
Peregrine Pharmaceuticals has a beta of 2.36, meaning that its stock price is 136% more volatile than the S&P 500. Comparatively, Peregrine Pharmaceuticals’ peers have a beta of 1.24, meaning that their average stock price is 24% more volatile than the S&P 500.
Peregrine Pharmaceuticals peers beat Peregrine Pharmaceuticals on 7 of the 12 factors compared.
Peregrine Pharmaceuticals Company Profile
Peregrine Pharmaceuticals, Inc. (Peregrine) is a biopharmaceutical company. The Company operates through two segments: Peregrine, which is engaged in the research and development of monoclonal antibodies for the treatment of cancer, and Avid, which is engaged in providing contract manufacturing services for third party customers on a fee-for-service basis while also supporting its internal drug development efforts. Bavituximab is its lead immunotherapy candidate. Bavituximab is a monoclonal antibody that targets and binds to phosphatidylserine (PS), a immunosuppressive molecule that is usually located inside the membrane of healthy cells, but then flips and becomes exposed on the outside of cells in the tumor microenvironment, causing the tumor to evade immune detection. The Company’s subsidiary is Avid Bioservices, Inc. (Avid). Avid provides integrated current good manufacturing practices (cGMP) services from cell line development to commercial biomanufacturing.
Receive News & Ratings for Peregrine Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Peregrine Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.